This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Albireo Pharma (ALBO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Albireo Pharma (ALBO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.
Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.
Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Albireo Pharma (ALBO) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Albireo Pharma (ALBO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALBIREO PHARMA (ALBO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of 1.04% and -6.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ALBIREO PHARMA (ALBO) Q2 Earnings Expected to Decline
by Zacks Equity Research
ALBIREO PHARMA (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
by Zacks Equity Research
Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
by Zacks Equity Research
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
New Strong Sell Stocks for May 26th
by Zacks Equity Research
ALBO, EBMT, GAN, IRTC, and WLKP have been added to the Zacks Rank #5 (Strong Sell) List on May 26, 2021
New Strong Sell Stocks for May 19th
by Zacks Equity Research
ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021
ALBIREO PHARMA (ALBO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of -33.14% and -25.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 29th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for December 24th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for November 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for November 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Company News for Sep 9, 2020
by Zacks Equity Research
Companies in the news are: NKLA, BA, PTON, ALBO
Is the Options Market Predicting a Spike in Albireo Pharma (ALBO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Albireo Pharma (ALBO) stock based on the movements in the options market lately.
Albireo (ALBO) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Albireo (ALBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Albireo Down on Unimpressive Data From Mid-Stage NASH Study
by Zacks Equity Research
Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.
Are Options Traders Betting on a Big Move in Albireo (ALBO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Albireo (ALBO) stock based on the movements in the options market lately.
Why Albireo Pharma (ALBO) Stock Might be a Great Pick
by Zacks Equity Research
Albireo Pharma (ALBO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.